Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Front Immunol. 2022 Oct 27;13:966766. doi: 10.3389/fimmu.2022.966766. eCollection 2022.
Current treatments for central nervous system (CNS) inflammatory demyelinating diseases (IDDs) include corticosteroids, plasma exchange, intravenous immunoglobulin, and immunosuppressant drugs. However, some patients do not respond well to traditional therapies. In recent years, novel drugs, such as monoclonal antibodies, targeting the complement component C5, CD19 on B cells, and the interleukin-6 (IL-6) receptor, have been used for the treatment of patients with refractory CNS IDDs. Among these, tocilizumab and satralizumab, humanized monoclonal antibodies against the IL-6 receptor, have shown beneficial effects in the treatment of this group of diseases. In this review, we summarize current research progress and prospects relating to anti-IL-6 therapies in CNS IDDs.
目前治疗中枢神经系统（CNS）炎症性脱髓鞘疾病（IDD）的方法包括皮质类固醇、血浆置换、静脉注射免疫球蛋白和免疫抑制剂。然而，一些患者对传统疗法反应不佳。近年来，新型药物如靶向补体成分 C5、B 细胞上的 CD19 和白细胞介素-6（IL-6）受体的单克隆抗体已被用于治疗难治性 CNS IDD 患者。其中，托珠单抗和沙利鲁单抗，抗 IL-6 受体的人源化单克隆抗体，在治疗这类疾病方面显示出了有益的效果。在这篇综述中，我们总结了目前关于 CNS IDD 中抗 IL-6 治疗的研究进展和前景。
